Login / Signup

Infliximab and its biosimilar produced similar first-year therapy outcomes in patients with inflammatory bowel disease.

Anne NikkonenKaija-Leena Kolho
Published in: Acta paediatrica (Oslo, Norway : 1992) (2019)
The first-year therapy outcomes of infliximab and its biosimilar were comparable. There were no alarming signs of differences in safety.
Keyphrases
  • patients with inflammatory bowel disease
  • type diabetes
  • metabolic syndrome
  • mesenchymal stem cells
  • bone marrow
  • skeletal muscle